The Committee on Medicines for Human Use (CHMP, by its acronym in English) do European Medicines Agency (EMA) is in the process of reviewing BioNTech / Pfizer’s Comirnaty vaccine to decide whether it recommends expanding its use.
This work includes the results of an ongoing clinical study involving children aged 5 to 11 years. The CHMP’s opinion will be forwarded to the European Commission, which in turn will communicate the final decision.
The EMA will communicate the result of your assessment, unless you require additional information, within a few months
Comirnaty was first licensed in the EU in December 2020. This vaccine contains a messenger RNA molecule (MRNA) with instructions for making a protein, known as a spike protein, naturally present in SARS-CoV-2.
In this way, it works by preparing the body to defend itself against the aforementioned virus. Its administration consists of two injections, with an interval of 3 weeks between one and the other. The EMA will communicate the result of your assessment, unless you require additional information, within a few months.
Source: SYNC
Rights: Creative Commons.
.